Cancer News and Research

Latest Cancer News and Research

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Vanishing bile duct syndrome refers to a group of disorders characterized by destruction and disappearance of intrahepatic (inside the liver) bile ducts. Multiple causes have been identified including infections, malignancies, autoimmune conditions and adverse effects of medications. The usual course of this condition is variable and many patients with VBDS respond to treatment of the underlying condition and/ or removal of the offending agent. However, others progress to cirrhosis and end stage liver disease requiring liver transplantation.

31 Jul 2010

COGS receives $10 million renewal grant from National Institute of Mental Health

The six-site Consortium on the Genetics of Schizophrenia (COGS), led by the director of the Schizophrenia Program at the University of California, San Diego School of Medicine, has received a $10 million renewal grant from the National Institute of Mental Health (NIMH), one of the National Institutes of Health. The grant funds an ongoing, multiple-site collaboration examining the genetic architecture of the causes and abnormalities related to schizophrenia.

31 Jul 2010

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Today, Formatech, Inc. announced that it has selected Femta's FM101 therapeutic candidate to be enrolled in its Fillanthropy Program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in support of Femta's upcoming clinical trials.

31 Jul 2010

Pathwork Diagnostics enters into research collaboration with Novartis

Pathwork Diagnostics Inc., a molecular diagnostics company focused on oncology, today announced that it has entered into a research collaboration with Novartis. The parties intend to discover clinically meaningful biomarker signatures that can serve as the basis for diagnostics across a range of cancer types. Under the terms of the agreement, both parties have rights to develop and commercialize the diagnostic products. Financial terms were not disclosed.

31 Jul 2010

NHS Breast Screening Programme detects 1,500 invasive cancers

A new report has revealed that the NHS Breast Screening Programme detected nearly 1,500 cases of the disease in 2008-09 in Scotland.Since 1991, the programme has screened over 2.3 million women in Scotland and has led to the diagnosis of approximately 17,000 breast cancers.The latest statistics, which are published by ISD Scotland, show that about three-quarters of women who were invited to attend screening in 2008-09 accepted their invitation.

31 Jul 2010

Commonwealth Pain Specialists offers treatment with CTT's Calmare Pain Therapy device

Competitive Technologies, Inc. announced today that Commonwealth Pain Specialists, the premier pain management center in Richmond and Central Virginia, is treating patients suffering from chronic, intense neuropathic pain using CTT's Calmare® Pain Therapy medical device.

31 Jul 2010

Exposure of mBM-MSCs to VPA increases hepatic differentiation

Recent studies suggest that MSCs possess a greater differentiation potential than once thought and several hepatic differentiation protocols from bone marrow cells have been established. However, the incidence of bone marrow-derived hepatocytes was low. Moreover, a long culture period is needed in most cases.

31 Jul 2010

Sodium Working Group recommends reducing sodium intake among Canadians

The federally-mandated Sodium Working Group has released the Sodium Reduction Strategy for Canada. The three-pronged strategy contains six over-arching and 27 specific recommendations for a population health strategy for reducing sodium intake among Canadians.

31 Jul 2010

QVC organizes special two-hour "designer charity sale" to benefit OCRF

"Charity chic" is back in style this summer as QVC once again joins forces with the Ovarian Cancer Research Fund to broadcast QVC Presents Super Saturday Live, benefiting OCRF.

31 Jul 2010

Consumers who have MMS should stop using it immediately, FDA warns

The U.S. Food and Drug Administration is warning consumers not to take Miracle Mineral Solution, an oral liquid solution also known as "Miracle Mineral Supplement" or "MMS." The product, when used as directed, produces an industrial bleach that can cause serious harm to health.

31 Jul 2010

Patients with malignant gastrointestinal disease show high prevalence of malnutrition

Malnutrition is an important factor, influencing both morbidity and recovery after surgery. The early detection of nutritional risk would allow early intervention, which may prevent later complications. A traditional nutritional assessment often includes dietary and medical evaluations to identify significant weight loss over time, significantly low or high body weight(BW), skinfold thickness, serum nutritional factor levels and functional measurements of muscle strength.

31 Jul 2010

Galangin mediates apoptosis of hepatocellular carcinoma cells through mitochondrial pathway: Study

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, particularly in China. However, HCC remains one of the more difficult cancers to treat. It is important to screen for new anti-cancer drugs. A number of dietary compounds possess anti-cancer properties. These dietary compounds may modify the activity of specific targets that control cell proliferation and apoptosis. Galangin could inhibit the methoxyresorufin O-demethylase activity of CYP1A2, CYP1A1 and P-form phenolsulfotransferase.

31 Jul 2010

CD74 can serve as prognostic marker for colorectal cancer

CD74 is a protein that is expressed in and on cells of the immune system, such as B lymphocytes and antigen presenting cells. This protein is known for its function in facilitating antigen presentation enabling the immune response. Additionally, Professor Shachar's lab has previously shown that CD74 serves as a survival receptor on cells of the immune system, and that its stimulation by its natural ligand -migration inhibitory factor (MIF)- prevents apoptosis (self destruction) of these cells. It was shown that CD74 is markedly expressed on numerous tumors - hematologic as well as epithelial, and can serve as a prognostic marker. CD74's expression and function on colon intestinal epithelial cells is controversial.

31 Jul 2010

Adequate calcium intake maintains optimum bone mass

A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.

31 Jul 2010

Microsulis launches Acculis percutaneous microwave tissue ablation system at ECIO

Microsulis Medical Ltd (MML), the leading company in microwave technology for medical devices, has successfully launched the Acculis percutaneous microwave tissue ablation system, Accu2i pMTA, at the second European Conference on Interventional Oncology (ECIO) in Florence, Italy. A revolutionary new device for destroying tumours, the system is a 1.8mm diameter closed water-cooled needle, with performance matching the existing Acculis open surgery MTA system.

31 Jul 2010

Epigenetic changes to DNA in breast cancers linked with environmental risk factors, tumor size: Study

Researchers from Brown University and the University of California San Francisco have found that epigenetic changes to DNA in breast cancers are related to environmental risk factors and tumor size, providing a window into the severity of the disease. The study is published in today's edition of PLoS Genetics. The researchers found that epigenetic profiles of tumors had a direct association with diet, alcohol, and tumor size.

31 Jul 2010

Functional MRI can be used to assess tumor viability

Pancreatic ductal adenocarcinoma (the disease commonly referred to as pancreatic cancer) carries the worst prognosis of any cancer. As current treatments offer minimal benefit, entirely new approaches are needed. Given the success of local therapies, as opposed to intravenous systemic therapies, for liver diseases (such as hepatocellular carcinoma), it is thought that similar local therapies may benefit patients with pancreatic cancer. To develop such therapies, it would be useful to devise targets that are easy to obtain and can indicate the efficacy of these new therapies in models of pancreatic cancer.

31 Jul 2010

ZIOPHARM second-quarter net loss from operations increases to $5.1 million

ZIOPHARM Oncology, Inc., a biopharmaceutical cancer company addressing unmet medical needs, today reported its financial results for the three months ended June 30, 2010 and provided an update on the Company's continued progress with its clinical programs.

30 Jul 2010

Paperwork for reimbursement prevents PCTs access to high-cost cancer drugs

The amount of paperwork that primary care trusts (PCTs) have to fill out in order to be reimbursed for cancer drugs is so great that they may be missing out on millions of pounds, a report suggests.

30 Jul 2010

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.

30 Jul 2010

Cancer News and Research

Latest Cancer News and Research

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

COGS receives $10 million renewal grant from National Institute of Mental Health

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Pathwork Diagnostics enters into research collaboration with Novartis

NHS Breast Screening Programme detects 1,500 invasive cancers

Commonwealth Pain Specialists offers treatment with CTT's Calmare Pain Therapy device

Exposure of mBM-MSCs to VPA increases hepatic differentiation

Sodium Working Group recommends reducing sodium intake among Canadians

QVC organizes special two-hour "designer charity sale" to benefit OCRF

Consumers who have MMS should stop using it immediately, FDA warns

Patients with malignant gastrointestinal disease show high prevalence of malnutrition

Galangin mediates apoptosis of hepatocellular carcinoma cells through mitochondrial pathway: Study

CD74 can serve as prognostic marker for colorectal cancer

Adequate calcium intake maintains optimum bone mass

Microsulis launches Acculis percutaneous microwave tissue ablation system at ECIO

Epigenetic changes to DNA in breast cancers linked with environmental risk factors, tumor size: Study

Functional MRI can be used to assess tumor viability

ZIOPHARM second-quarter net loss from operations increases to $5.1 million

Paperwork for reimbursement prevents PCTs access to high-cost cancer drugs

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in